Recent Investment Analysts’ Ratings Updates for BioVie (BIVI)

A number of firms have modified their ratings and price targets on shares of BioVie (NASDAQ: BIVI) recently:

• 10/19/2026 – BioVie was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/15/2026 – BioVie had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 10/11/2026 – BioVie was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/3/2026 – BioVie was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/5/2026 – BioVie was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Buying and Selling at BioVie

In related news, CEO Cuong Do purchased 15,210 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was acquired at an average price of $2.08 per share, with a total value of $31,636.80. Following the completion of the acquisition, the chief executive officer directly owned 16,117 shares in the company, valued at approximately $33,523.36. This trade represents a 1,676.96% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have purchased a total of 23,280 shares of company stock valued at $49,118 over the last three months. Company insiders own 16.70% of the company’s stock.

BioVie Inc (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for complex diseases with significant unmet medical needs. Its research programs have centered on neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease, as well as liver diseases associated with cirrhosis.

The company’s development portfolio has included NE3107, an investigational oral therapy being studied for potential anti-inflammatory and insulin-sensitizing effects in neurodegenerative conditions.